Tissue transglutaminase inhibitors over the past decade
Open Access
- 3 November 2025
- journal article
- review article
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 132, 118476
Abstract
No abstract availableKeywords
Funding Information
- Natural Sciences and Engineering Research Council of Canada
This publication has 98 references indexed in Scilit:
- GK921, a transglutaminase inhibitor, strengthens the antitumor effect of cisplatin on pancreatic cancer cells by inhibiting epithelial-to-mesenchymal transitionBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2023
- Transglutaminase 2: a novel therapeutic target for idiopathic pulmonary fibrosis using selective small molecule inhibitorsAmino Acids, 2021
- Transglutaminase 2 takes center stage as a cancer cell survival factor and therapy targetMolecular Carcinogenesis, 2019
- Allosteric inhibition site of transglutaminase 2 is unveiled in the N terminusAmino Acids, 2018
- Designing Dual Transglutaminase 2/Histone Deacetylase Inhibitors Effective at Halting Neuronal DeathChemMedChem, 2018
- Intracellular TG2 Activity Increases Microtubule Stability but is not Sufficient to Prompt Neurite GrowthNeuroscience Bulletin, 2016
- Transglutaminase 2 inhibitor abrogates renal cell carcinoma in xenograft modelsJournal of Cancer Research and Clinical Oncology, 2014
- Transglutaminase 2 reprogramming of glucose metabolism in mammary epithelial cells via activation of inflammatory signaling pathwaysInternational Journal of Cancer, 2013
- Irreversible Inhibitors of Tissue Transglutaminase2011
- A Continuous Spectrophotometric Linked Enzyme Assay for Transglutaminase ActivityAnalytical Biochemistry, 1999